RLAY Description — Relay Therapeutics Inc

Relay Therapeutics is a clinical-stage precision medicines company. Co. has deployed its technology platform to build a pipeline of product candidates to address targets in precision medicine where there is clear evidence linking target proteins to disease and where molecular diagnostics can identify relevant patients for treatment. Co. has initiated a clinical trial for one of its product candidates, RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced or metastatic FGFR2-altered solid tumors. The U.S. Food and Drug Administration has granted orphan drug designation to RLY-4008 for the treatment of cholangiocarcinoma.

Company Name: 
Relay Therapeutics Inc
Number of ETFs Holding RLAY: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 
 ETF   RLAY Weight   RLAY Amount 
 XBI   0.98%   $64,427,899         
 VTI   0.00%   $53,375,693         
 VB   0.04%   $45,038,748         
 IWM   0.06%   $28,976,608         
 VBK   0.09%   $25,926,885         
 VXF   0.02%   $18,302,332         
 IWN   0.11%   $12,037,256         
 VHT   0.02%   $4,124,833         
 VTWO   0.06%   $3,473,463         
 ITOT   0.00%   $1,391,598         
List of all 27 ETFs holding RLAY »
Quotes delayed 20 minutes

Email EnvelopeFree RLAY Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Strong Buy (3.50 out of 4)
56th percentile
(ranked higher than approx. 56% of all stocks covered)
Based on data provided by Zacks Investment Research via

ETFs Holding RLAY | Relay Therapeutics Inc | ETF Channel |

Copyright © 2010 - 2023, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.